fluorodeoxyglucose f18 has been researched along with Bone Loss, Osteoclastic in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ansquer, C; Drui, D; Gahier Penhoat, M; Guillot, P; Maugars, Y; Mirallie, E | 1 |
Alaee, F; Chatziioannou, AF; Dougall, WC; Lieberman, JR; Petrigliano, FA; Stout, D; Sugiyama, O; Virk, MS | 1 |
Blake, GM; Cook, G; Fogelman, I; Frost, ML; Marsden, PK | 1 |
3 other study(ies) available for fluorodeoxyglucose f18 and Bone Loss, Osteoclastic
Article | Year |
---|---|
Contribution of 18-FDG PET/CT to brown tumor detection in a patient with primary hyperparathyroidism.
Topics: Adenoma; Aged; Biopsy; Bone Neoplasms; Bone Resorption; Fluorodeoxyglucose F18; Humans; Hyperparathyroidism, Primary; Male; Parathyroid Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Technetium Tc 99m Sestamibi | 2017 |
Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.
Topics: Animals; Bone Morphogenetic Proteins; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Fluorodeoxyglucose F18; Hindlimb; Humans; Male; Mice; Mice, SCID; Osteoclasts; Osteogenesis; Positron-Emission Tomography; Prostatic Neoplasms; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Recombinant Fusion Proteins; Signal Transduction; Tibia; Tumor Burden; X-Ray Microtomography | 2011 |
Dissociation between global markers of bone formation and direct measurement of spinal bone formation in osteoporosis.
Topics: Absorptiometry, Photon; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Kinetics; Lumbar Vertebrae; Middle Aged; Models, Theoretical; Osteoporosis; Osteoporosis, Postmenopausal; Positron-Emission Tomography; Postmenopause; Radiopharmaceuticals; Time Factors | 2004 |